|
Home:
Educational Supplement: Appendix
NIH
Consensus Development Conference on
Adjuvant Therapy for Breast Cancer
IV.
Adjuvant Chemotherapy
Overview: Progress in Systemic
Chemotherapy of Primary Breast Cancer
Gabriel N. Hortobagyi, M.D., FACP.
Is Her-2/neu a Predictor of Anthracycline
Utility in Adjuvant Therapy? A Qualified Yes.
Peter M. Ravdin, M.D., Ph.D.
Is HER-2/neu a Predictor of Anthracycline
Utility? No.
George W. Sledge, Jr., M.D.
Adjuvant Chemotherapy: Taxanes—the
“Pro” Position
I. Craig Henderson, M.D.
Evaluating the Use of Paclitaxel Following
Doxorubicin/Cyclophosphamide
in Patients With Breast Cancer and Positive Axillary Nodes
Eleftherios P. Mamounas, M.D.
Taxanes
in the Adjuvant Setting: Why Not Yet?
Martine J. Piccart, M.D., Ph.D.
Preoperative
Chemotherapy: NSABP Protocols B-18 and B-27
Norman Wolmark, M.D.
Who Should Not Receive
Chemotherapy?—International Databases
Jonas C. Bergh, M.D., Ph.D.
Who Should Not Receive Chemotherapy?—U.S.
Databases and Trials
Monica Morrow, M.D.
A Prospective, Randomized Comparison of Two Doses of Combination
Alkyating
Agents (AA) as Consolidation After CAF in High-Risk Primary Breast
Cancer
Involving Ten or More Axillary Lymph Nodes (LN): Preliminary Results
of
CALGB 9082/SWOG 9114/NCIC MA-13
William P. Peters, M.D., Ph.D.
Overview of the Six Randomized
Adjuvant Trials of High-Dose Chemotherapy
in Breast Cancer
Karen H. Antman, M.D
|
